摘要
目的:观察芪苈强心胶囊联合沙库巴曲缬沙坦治疗老年急性心肌梗死(AMI)后心力衰竭(HF)患者的效果。方法:选取2020年10月至2021年10月该院收治的100例老年AMI后HF患者进行前瞻性研究,采用随机数字表法分为观察组(50例)和对照组(50例)。两组均予以常规治疗,在此基础上对照组采用沙库巴曲缬沙坦治疗,观察组在对照组基础上联合芪苈强心胶囊治疗,两组均持续治疗3个月。比较两组临床疗效、治疗前后血清内皮素-1(ET-1)、左心室射血分数(LVEF)、6 min步行试验距离(6MWT)和血浆氨基末端脑钠肽前体(NT-proBNP)水平,以及不良反应发生率。结果:观察组治疗总有效率为92.00%(46/50),高于对照组的76.00%(38/50),差异有统计学意义(P<0.05);治疗后,观察组血清ET-1水平和血浆NT-proBNP水平低于对照组,LVEF水平和6MWT水平均高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合沙库巴曲缬沙坦治疗老年AMI后HF患者可提高治疗总有效率、LVEF水平和6MWT水平,以及降低血清ET-1水平和血浆NT-proBNP水平,效果优于单纯沙库巴曲缬沙坦治疗。
Objective: To observe effects of Qili Qiangxin capsules combined with Sacubitril/Valsartan in treatment of elderly patients with heart failure(HF) after acute myocardial infarction(AMI). Methods: A total of 100 elderly patients with post-AMI HF admitted to our hospital from October 2020 to October 2021 were selected for prospective study, and were divided into observation group(50 cases) and control group(50 cases)by random number table method. Both groups received conventional treatment. On this basis, the control group was treated with Sacubitril/Valsartan,while the observation group was treated with Qili Qiangxin capsules on the basis of that of the control group. Both groups were treated continuously for 3 months. The clinical efficacy, the serum endothelin-1(ET-1) level, the left ventricular ejection fraction(LVEF), the 6-min walking test distance(6MWT), the plasma N-terminal pro-brain natriuretic peptide(NT-proBNP), and the incidence of adverse reactions were compared between the two groups before and after the treatment. Results: The total effective rate of treatment in the observation group was 92.00%(46/50), which was higher than the control group of 76.00%(38/50), and the difference was statistically significant(P<0.05). After the treatment, the serum ET-1 level and the plasma NT-proBNP level of the observation group were lower than those of the control group;the levels of LVEF and 6MWT were higher than those of the control group;and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Qili Qiangxin capsules combined with Sacubitril/Valsartan in the treatment of the elderly patients with HF after AMI can improve the total effective rate, the LVEF levels and the 6MWT levels, and reduce the serum ET-1 levels and the plasma NT-proBNP levels. Moreover, it is superior to single Sacubitril/Valsartan.
作者
谢自勤
丁克芬
罗赟
刘向荣
XIE Ziqin;DING Kefen;LUO Yun;LIU Xiangrong(Department of Cardiovascular Internal Medicine of Yudu County People’s Hospital,Ganzhou 342300 Jiangxi,China)
出处
《中国民康医学》
2022年第13期80-82,共3页
Medical Journal of Chinese People’s Health
基金
赣州市指导性科技计划项目(GZ2021ZSF606)。
关键词
急性心肌梗死
心力衰竭
芪苈强心胶囊
沙库巴曲缬沙坦
心功能
不良反应
Acute myocardial infarction
Heart failure
Qili Qiangxin capsule
Sacubitril/Valsartan
Cardiac function
Adverse reaction
作者简介
谢自勤(1991.07-),女,汉族,江西赣州人,本科,主治医师,研究方向为心血管内科学。
